Latest Vanda Pharmaceuticals Inc (VNDA) Headlines
Vanda Pharmaceuticals Has Returned 21.1% Since SmarTrend Recommendation (VNDA)
Comtex SmarTrend(R) - Mon Mar 10, 11:11AM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 2 months, Vanda Pharmaceuticals has returned 21.09% as of today's recent price of $15.13.
Financial Results Releases and Schedules, Clinical Study Results, Partnerships, and Senior-Level Appointments - Analyst Notes on Arena, Horizon Pharma, Enanta, Vanda, and PTC
PR Newswire - Wed Mar 05, 2:30PM CST
Editor Note: For more information about this release, please scroll to bottom.
Shares of VNDA Up 20.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 03, 9:51AM CST
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 2 months, Vanda Pharmaceuticals has returned 20.61% as of today's recent price of $15.07.
Blind Adventurer, Erik Weihenmayer, Launches National Campaign to Raise Awareness of Non-24-Hour Sleep-Wake Disorder
PR Newswire - Fri Feb 28, 6:00AM CST
Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that it has partnered with Erik Weihenmayer, a world-renowned adventurer and the only blind person to climb Mount Everest, to support the Non-24 Share More Campaign and launch the expert podcast series available at Non-24.com. This national education initiative aims to raise awareness for Non-24-Hour Sleep-Wake Disorder (Non-24), a serious, chronic circadian rhythm disorder that affects up to 70 percent of people who are totally blind.[1]
5 Monster Momentum Stocks to Trade
at The Street - Tue Feb 25, 1:23PM CST
Momentum traders and trend-following traders are basking in profits in this current market.
10-K: VANDA PHARMACEUTICALS INC.
Edgar Online - Tue Feb 25, 6:04AM CST
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Vanda Reports Wider-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 10:30AM CST
Vanda Pharma reported fourth quarter 2013 net loss per share of 23 cents, wider than the Zacks Consensus Estimate of a loss of 18 cents
Vanda Pharmaceuticals' Q4 Loss Widens on Higher Expenses
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 13, 11:02AM CST
Vanda Pharmaceuticals , a biopharmaceutical company focused on developing therapies to treat central nervous system disorders, reported modest product growth and a wider net loss before the opening bell today. In its fourth-quarter report , Vanda...
Vanda Pharmaceuticals Reports Fourth Quarter 2013 and Full Year 2013 Results
PR Newswire - Thu Feb 13, 6:00AM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2013.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 08, 7:00AM CST
What kind of week do you suppose Peyton Manning, star quarterback of the Denver Broncos, had this week? After the horrible Super Bowl loss to the Seattle Seahawks, it probably wasn't too great for Manning and the rest of the Denver team. ...
Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market
PR Newswire - Tue Feb 04, 8:05AM CST
Market Briefing for leading pharma advancers along with clinical data reveals biotech company is on the verge of fulfilling glaring market need: Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), Pfizer Inc. (NYSE: PFE), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Alcobra Ltd. (NASDAQ: ADHD), Horizon Pharma, Inc. (NASDAQ: HZNP) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)
Nasdaq stocks posting largest percentage decreases
AP - Mon Feb 03, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why Vanda Pharmaceuticals Won Big Today
David Williamson, The Motley Fool - Motley Fool - Fri Jan 31, 5:47PM CST
Vanda Pharmaceuticals received a very important FDA approval today for its drug Hetlioz, a melatonin receptor agonist that treats non-24 hour sleep wake disorder in the blind, for people who cannot see sunlight and thus have their circadian rhythms...
A Short-Lived FDA Approval Pop
Brian Orelli, The Motley Fool - Motley Fool - Fri Jan 31, 4:21PM CST
I've never been so right and so wrong so quickly. On Monday, I predicted that Vanda Pharmaceuticals would gain Food and Drug Administration approval for its sleep aid Hetlioz, but that the approval was far from a sure thing, providing for a...
FDA clears first drug for blindness sleep disorder
AP - Fri Jan 31, 3:52PM CST
WASHINGTON (AP) — U.S. health regulators on Friday approved the first drug to treat a sleep disorder that mainly afflicts the blind.
FDA Approves HETLIOZ(TM) (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder
PR Newswire - Fri Jan 31, 12:45PM CST
Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved HETLIOZ(TM) (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ(TM) is the first FDA approved medication for Non-24.
Will the FDA Approve Vanda's Hetlioz?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jan 27, 9:12PM CST
It's easy to see how Vanda Pharmaceuticals can gain Food and Drug Administration approval for its sleep aid Hetlioz by the end of the week. In briefing documents for an advisory panel, the FDA seemed to be convinced the drug works. The panel of...
Vanda Pharmaceuticals to Announce Fourth Quarter 2013 Financial Results on February 13, 2014
PR Newswire - Thu Jan 23, 4:00PM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the fourth quarter of 2013 on Thursday, February 13, 2014, before the market opens.
Vanda Pharmaceuticals Has Returned 21.1% Since SmarTrend Recommendation (VNDA)
Comtex SmarTrend(R) - Mon Mar 10, 11:11AM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 2 months, Vanda Pharmaceuticals has returned 21.09% as of today's recent price of $15.13.
Financial Results Releases and Schedules, Clinical Study Results, Partnerships, and Senior-Level Appointments - Analyst Notes on Arena, Horizon Pharma, Enanta, Vanda, and PTC
PR Newswire - Wed Mar 05, 2:30PM CST
Editor Note: For more information about this release, please scroll to bottom.
Shares of VNDA Up 20.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 03, 9:51AM CST
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 2 months, Vanda Pharmaceuticals has returned 20.61% as of today's recent price of $15.07.
Blind Adventurer, Erik Weihenmayer, Launches National Campaign to Raise Awareness of Non-24-Hour Sleep-Wake Disorder
PR Newswire - Fri Feb 28, 6:00AM CST
Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that it has partnered with Erik Weihenmayer, a world-renowned adventurer and the only blind person to climb Mount Everest, to support the Non-24 Share More Campaign and launch the expert podcast series available at Non-24.com. This national education initiative aims to raise awareness for Non-24-Hour Sleep-Wake Disorder (Non-24), a serious, chronic circadian rhythm disorder that affects up to 70 percent of people who are totally blind.[1]
5 Monster Momentum Stocks to Trade
at The Street - Tue Feb 25, 1:23PM CST
Momentum traders and trend-following traders are basking in profits in this current market.
10-K: VANDA PHARMACEUTICALS INC.
Edgar Online - Tue Feb 25, 6:04AM CST
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Vanda Reports Wider-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 10:30AM CST
Vanda Pharma reported fourth quarter 2013 net loss per share of 23 cents, wider than the Zacks Consensus Estimate of a loss of 18 cents
Vanda Pharmaceuticals' Q4 Loss Widens on Higher Expenses
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 13, 11:02AM CST
Vanda Pharmaceuticals , a biopharmaceutical company focused on developing therapies to treat central nervous system disorders, reported modest product growth and a wider net loss before the opening bell today. In its fourth-quarter report , Vanda...
Vanda Pharmaceuticals Reports Fourth Quarter 2013 and Full Year 2013 Results
PR Newswire - Thu Feb 13, 6:00AM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2013.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 08, 7:00AM CST
What kind of week do you suppose Peyton Manning, star quarterback of the Denver Broncos, had this week? After the horrible Super Bowl loss to the Seattle Seahawks, it probably wasn't too great for Manning and the rest of the Denver team. ...
Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market
PR Newswire - Tue Feb 04, 8:05AM CST
Market Briefing for leading pharma advancers along with clinical data reveals biotech company is on the verge of fulfilling glaring market need: Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), Pfizer Inc. (NYSE: PFE), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Alcobra Ltd. (NASDAQ: ADHD), Horizon Pharma, Inc. (NASDAQ: HZNP) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)
Nasdaq stocks posting largest percentage decreases
AP - Mon Feb 03, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why Vanda Pharmaceuticals Won Big Today
David Williamson, The Motley Fool - Motley Fool - Fri Jan 31, 5:47PM CST
Vanda Pharmaceuticals received a very important FDA approval today for its drug Hetlioz, a melatonin receptor agonist that treats non-24 hour sleep wake disorder in the blind, for people who cannot see sunlight and thus have their circadian rhythms...
A Short-Lived FDA Approval Pop
Brian Orelli, The Motley Fool - Motley Fool - Fri Jan 31, 4:21PM CST
I've never been so right and so wrong so quickly. On Monday, I predicted that Vanda Pharmaceuticals would gain Food and Drug Administration approval for its sleep aid Hetlioz, but that the approval was far from a sure thing, providing for a...
FDA clears first drug for blindness sleep disorder
AP - Fri Jan 31, 3:52PM CST
WASHINGTON (AP) — U.S. health regulators on Friday approved the first drug to treat a sleep disorder that mainly afflicts the blind.
FDA Approves HETLIOZ(TM) (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder
PR Newswire - Fri Jan 31, 12:45PM CST
Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved HETLIOZ(TM) (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ(TM) is the first FDA approved medication for Non-24.
Will the FDA Approve Vanda's Hetlioz?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jan 27, 9:12PM CST
It's easy to see how Vanda Pharmaceuticals can gain Food and Drug Administration approval for its sleep aid Hetlioz by the end of the week. In briefing documents for an advisory panel, the FDA seemed to be convinced the drug works. The panel of...
Vanda Pharmaceuticals to Announce Fourth Quarter 2013 Financial Results on February 13, 2014
PR Newswire - Thu Jan 23, 4:00PM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the fourth quarter of 2013 on Thursday, February 13, 2014, before the market opens.
